- Hitting the target with antithrombotic
therapy.
Overview: antithrombotics and their indications Anticoagulants or antithrombotics, known to the public as "blood thinners" have been used successfully since the 1940s to reduce secondary thrombus formation. (1) Although they do not "thin" blood or dissolve clots, antithrombotics limit or prevent clotting in atrial fibrillation, percutaneous cardiac intervention (PCI), ......
- Point-of-care testing in oral anticoagulation: what is
the point?
Warfarin is commonly used for oral anticoagulant therapy (OAT) in patients predisposed to thromboembolism (TE) or being treated for thrombosis. The efficacy of warfarin therapy is followed by monitoring the prothrombim time (PT) and international normalized ration (INR), which were, until recently, only performed in laboratories. Advances in point-of-care testing ......
- Pushing Aside an Industry Standard
HEADNOTE The Medicines Company's blood thinner Angiomax is fast replacing heparin as the drug of choice for patients undergoing cardiac procedures The Medicines Company has an ambitious goal: It wants to cut the world of invasive cardiac surgery and interventions free from one of its pharmacological moorings. The blood thinner ......
- New drug helps prevent blood clots after hip, knee
surgery. (NH News Notes).
A new drug, fondaparinux sodium 2.5 mg injection (Arixtra[R]) from Organon, is now available to help prevent blood clots resulting from deep-vein thrombosis (DVT) in individuals who have undergone hip or knee replacement surgery, or surgery for a hip fracture. DVT can lead to pulmonary embolism (PE), a life-threatening complication ......
- Administration of a glycoprotein IIb/IIIa receptor
blocker with a thienopyridine derivative does not increase the risk of
thrombocytopenia (1).
ABSTRACT. The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI). Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a high loading dose of clopidogrel (thienopyridine) with abciximab (IIb/IIIa receptor inhibitor) ......
- Nanowire coating for bone implants.
University of Arkansas researchers have found a simple, inexpensive way to create a nanowire coating on the surface of biocompatible titanium that can be used to create more effective surfaces for hip replacement, dental reconstruction and vascular stenting. Further, the material can easily be sterilized using ultraviolet light and ......
- Cardica and Cook Medical enter new collaboration
agreement to develop and commercialize closure device for heart
defects.
Cardica, Inc. (Redwood City, CA) and Cook Medical (Bloomington, IN) entered into an agreement to develop and commercialize a specialized device designed to close the patent foramen ovale (PFO), a relatively common heart defect present in approximately 15 to 20 percent of the general population. Under the terms of ......